Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ALIM Cowen Maintains Bullish Stance On Alimera On The Heels Of Iluvien FDA Approval http://www.smarteranalyst.com/2014/10/03/cowen-maintains-bullish-stance-alimera-heels-iluvien-fda-approval/
$MACK Merrimack: Brean Capital Highlights Key Takeaways From Management Meeting http://www.smarteranalyst.com/2014/10/03/merrimack-brean-capital-highlights-key-takeaways-management-meeting/
$MACK Merrimack: Brean Capital Highlights Key Takeaways From Management Meeting http://www.smarteranalyst.com/2014/10/03/merrimack-brean-capital-highlights-key-takeaways-management-meeting/
$NEPT Neptune: Phase 2 Topline Win Welcomes Neptune Into Prescription Omega-3 League, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/03/neptune-phase-2-topline-win-welcomes-neptune-prescription-omega-3-league-says-h-c-wainwright/
$NEPT Neptune: Phase 2 Topline Win Welcomes Neptune Into Prescription Omega-3 League, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/03/neptune-phase-2-topline-win-welcomes-neptune-prescription-omega-3-league-says-h-c-wainwright/
$AVNR Cowen Maintains Outperform On Avanir Ahead Of Full Data Release From Phase 2 AVP-923 http://www.smarteranalyst.com/2014/10/03/cowen-maintains-outperform-avanir-ahead-full-data-release-phase-2-avp-923/
$AVNR Cowen Maintains Outperform On Avanir Ahead Of Full Data Release From Phase 2 AVP-923 http://www.smarteranalyst.com/2014/10/03/cowen-maintains-outperform-avanir-ahead-full-data-release-phase-2-avp-923/
$BIIB Biogen: Cowen Analyst Sheds Light On Eloctate’s Rejection By UNH http://www.smarteranalyst.com/2014/10/03/biogen-cowen-analyst-sheds-light-eloctates-rejection-unh/
$TKMR Tekmira: We Have Accelerated Our Ebola Assumptions Which Drives Additional Upside, Says Maxim http://www.smarteranalyst.com/2014/10/03/tekmira-accelerated-ebola-assumptions-drives-additional-upside-says-maxim/
Tekmira: We Have Accelerated Our Ebola Assumptions Which Drives Additional Upside, Says Maxim http://www.smarteranalyst.com/2014/10/03/tekmira-accelerated-ebola-assumptions-drives-additional-upside-says-maxim/
$KERX Maxim Assigns Buy On Keryx Following Issuance Of Additional Patent On Ferric Citrate http://www.smarteranalyst.com/2014/10/02/maxim-assigns-buy-keryx-following-issuance-additional-patent-ferric-citrate/
Another research note on $KERX from Maxim. http://www.smarteranalyst.com/2014/10/02/maxim-assigns-buy-keryx-following-issuance-additional-patent-ferric-citrate/
$ISR Maxim Group Maintains Buy On IsoRay Following Fiscal Year 2014 Results http://www.smarteranalyst.com/2014/10/02/maxim-group-maintains-buy-isoray-following-fiscal-year-2014-results/
$ISR Maxim Group Maintains Buy On IsoRay Following Fiscal Year 2014 Results http://www.smarteranalyst.com/2014/10/02/maxim-group-maintains-buy-isoray-following-fiscal-year-2014-results/
$ADHD Alcobra: Does The Pre-Data Selloff Imply A Failed Phase 3? Roth Capital Comments http://www.smarteranalyst.com/2014/10/02/alcobra-pre-data-selloff-imply-failed-phase-3-roth-capital-comments/
$ACHN Alpha BioPharma Initiates Buy On Achillion; Sees %56 Upside http://www.smarteranalyst.com/2014/10/02/alpha-biopharma-initiates-buy-achillion-sees-v-upside/
$KERX Brean Capital Comments On Keryx Following Issuance Of A New U.S. Patent http://www.smarteranalyst.com/2014/10/02/brean-capital-comments-keryx-following-issuance-new-u-s-patent/
$YUM Oppenheimer Reiterates Outperform On Yum! Ahead Of 3Q Release And Guidance Update http://www.smarteranalyst.com/2014/10/02/oppenheimer-reiterates-outperform-yum-ahead-3q-release-guidance-update/
$CSCO Oppenheimer Highlights Takeaways From Cisco’s Investor Event http://www.smarteranalyst.com/2014/10/02/oppenheimer-highlights-takeaways-ciscos-investor-event/
$CSCO Oppenheimer Highlights Takeaways From Cisco’s Investor Event http://www.smarteranalyst.com/2014/10/02/oppenheimer-highlights-takeaways-ciscos-investor-event/
$ZGNX Oppenheimer Maintains Bullish Stance On Zogenix Following sNDA Filling For Abuse Deterrent Zohydro Formulation http://www.smarteranalyst.com/2014/10/02/oppenheimer-maintains-bullish-stance-zogenix-following-snda-filling-abuse-deterrent-zohydro-formulation/
$ZGNX Oppenheimer Maintains Bullish Stance On Zogenix Following sNDA Filling For Abuse Deterrent Zohydro Formulation http://www.smarteranalyst.com/2014/10/02/oppenheimer-maintains-bullish-stance-zogenix-following-snda-filling-abuse-deterrent-zohydro-formulation/ …
$IG $VRX Oppenheimer Reiterates Outperform On Igi Laboratories On The Heels Of A New Deal With Valeant http://www.smarteranalyst.com/2014/10/02/oppenheimer-reiterates-outperform-igi-laboratories-heels-new-deal-valeant/
$ECYT Cowen Remains Bullish On Endocyte Following Data Presentation At ESMO http://www.smarteranalyst.com/2014/10/01/cowen-remains-bullish-endocyte-following-data-presentation-esmo/
$EXEL Exelixis Remains Market Perform At Cowen Despite Positive Results From coBRIM http://www.smarteranalyst.com/2014/10/01/exelixis-remains-market-perform-cowen-despite-positive-results-cobrim/
$EXEL Exelixis Remains Market Perform At Cowen Despite Positive Results From coBRIM http://www.smarteranalyst.com/2014/10/01/exelixis-remains-market-perform-cowen-despite-positive-results-cobrim/
$ALXN Cowen Provides Update On Alexion Following Meetings With Management http://www.smarteranalyst.com/2014/10/01/cowen-provides-update-alexion-following-meetings-management/
$GILD Gilead Continues To Raise The Bar In HCV, Says Cowen http://www.smarteranalyst.com/2014/10/01/gilead-continues-raise-bar-hcv-says-cowen/
$GILD Gilead Continues To Raise The Bar In HCV, Says Cowen http://www.smarteranalyst.com/2014/10/01/gilead-continues-raise-bar-hcv-says-cowen/
$ARIA Ariad: AP26113 Data Is Impressive But Shares Are Fairly Valued, Says Cowen http://www.smarteranalyst.com/2014/10/01/ariad-ap26113-data-impressive-shares-fairly-valued-says-cowen/
$ARIA Ariad: AP26113 Data Is Impressive But Shares Are Fairly Valued, Says Cowen http://www.smarteranalyst.com/2014/10/01/ariad-ap26113-data-impressive-shares-fairly-valued-says-cowen/
$REGN Roth Capital Reiterates Buy On Regeneron Pharmaceuticals Following Positive Trial Results http://www.smarteranalyst.com/2014/10/01/roth-capital-reiterates-buy-regeneron-pharmaceuticals-following-positive-trial-results/
$REGN Roth Capital Reiterates Buy On Regeneron Pharmaceuticals Following Positive Trial Results http://www.smarteranalyst.com/2014/10/01/roth-capital-reiterates-buy-regeneron-pharmaceuticals-following-positive-trial-results/
$RGSE Roth Capital Comments On Real Goods Solar In Light Of Large Commercial Exit http://www.smarteranalyst.com/2014/10/01/roth-capital-comments-real-goods-solar-light-large-commercial-exit/
$RGSE Roth Capital Comments On Real Goods Solar In Light Of Large Commercial Exit http://www.smarteranalyst.com/2014/10/01/roth-capital-comments-real-goods-solar-light-large-commercial-exit/
$SRPT Roth Capital Still Sees 51% Upside For Sarepta’s Stock http://www.smarteranalyst.com/2014/10/01/roth-capital-still-sees-51-upside-sareptas-stock/
$SRPT Roth Capital Still Sees 51% Upside For Sarepta’s Stock http://www.smarteranalyst.com/2014/10/01/roth-capital-still-sees-51-upside-sareptas-stock/
$EBAY Topeka Capital Maintains Hold On Ebay On The Heels Of PayPal Split http://www.smarteranalyst.com/2014/10/01/topeka-capital-maintains-hold-ebay-heels-paypal-split/
$EBAY Topeka Capital Maintains Hold On Ebay On The Heels Of PayPal Split http://www.smarteranalyst.com/2014/10/01/topeka-capital-maintains-hold-ebay-heels-paypal-split/
$FB Topeka Capital Assigns Buy On Facebook Following Examination Of Oculus Rift Developer Headset http://www.smarteranalyst.com/2014/10/01/topeka-capital-assigns-buy-facebook-following-examination-oculus-rift-developer-headset/